Evidence map›Paper›PMID 42725188›Full record

ArticleTransplantation direct2026

Predictive Value of Perfusate Cell-free DNA During Hypothermic and Normothermic Machine Perfusion of Donor Kidneys.

Karim Bousnina, Julia S Slagter, Yitian Fang, Ruben G Boers, Joachim B Boers, Sebastiaan Heidt, Wilfred F J van IJcken, Joost Gribnau, Robert C Minnee, Martin J Hoogduijn and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Karim BousninaDivision of Nephrology and Transplantation, Department of Internal Medicine, Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID https://orcid.org/0009-0005-9510-9002
Julia S SlagterDivision of HPB and Transplant Surgery, Department of Surgery, Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
Yitian FangDivision of HPB and Transplant Surgery, Department of Surgery, Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
Ruben G BoersDepartment of Developmental Biology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Joachim B BoersDepartment of Developmental Biology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Sebastiaan HeidtDivision of Nephrology and Transplantation, Department of Internal Medicine, Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
Wilfred F J van IJckenErasmus Center for Biomics, Erasmus University Medical Center, Rotterdam, the Netherlands.
Joost GribnauDepartment of Developmental Biology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Robert C MinneeDivision of HPB and Transplant Surgery, Department of Surgery, Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
Martin J HoogduijnDivision of Nephrology and Transplantation, Department of Internal Medicine, Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
Karin BoerDivision of Nephrology and Transplantation, Department of Internal Medicine, Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cell-free DNA (cfDNA) is a potential biomarker for graft (dys)function during machine perfusion, but its ability to predict posttransplant outcomes in donor kidneys remains unclear. Methods: We analyzed perfusate cfDNA from 57 hypothermic machine-perfused (HMP) and 56 normothermic machine-perfused (NMP) deceased donor kidneys. Nuclear cfDNA and mitochondrial cfDNA (mt-cfDNA) were quantified and compared across immediate graft function (IGF), delayed graft function (DGF), primary nonfunction (PNF), and discarded kidneys. Methylated DNA sequencing was used to analyze the cfDNA methylome during HMP to identify differentially methylated regions between IGF and PNF kidneys. Associations with donor characteristics and transplant outcomes, including serum creatinine, estimated glomerular filtration rate, and DGF duration, were assessed. Results: Perfusate cfDNA concentrations during HMP were significantly higher in PNF kidneys (0.72 ng/µL) compared with both IGF (0.48 ng/µL) and DGF kidneys (0.43 ng/µL; Conclusions: cfDNA-especially mt-cfDNA-measured during machine perfusion is associated with posttransplant graft outcome during both HMP and NMP. Therefore, it may serve as a candidate biomarker that warrants validation in larger prospective studies.

Identifiers

PMID42725188
PMCPMC13561204

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.